Skye Bioscience, Inc.
SKYE
$3.29
-$0.26-7.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -14.38% | 58.80% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 55.14% | 10.25% | |||
| Operating Income | -55.14% | -10.25% | |||
| Income Before Tax | -58.73% | -13.90% | |||
| Income Tax Expenses | 70.00% | -- | |||
| Earnings from Continuing Operations | -58.74% | -13.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -58.74% | -13.92% | |||
| EBIT | -55.14% | -10.25% | |||
| EBITDA | -55.90% | -10.40% | |||
| EPS Basic | -58.71% | -14.80% | |||
| Normalized Basic EPS | -59.49% | -15.97% | |||
| EPS Diluted | -58.71% | -14.80% | |||
| Normalized Diluted EPS | -59.49% | -15.97% | |||
| Average Basic Shares Outstanding | 0.02% | -0.79% | |||
| Average Diluted Shares Outstanding | 0.02% | -0.79% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||